Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
|Articles|November 1, 1998
Oncology NEWS International
- Oncology NEWS International Vol 7 No 11
- Volume 7
- Issue 11
RTOG to Conduct Multicenter Study of Prostate Brachytherapy
PHILADELPHIA--The Radiation Therapy Oncology Group (RTOG) has just begun work on a potentially ground-breaking study of the use of radioactive seed implants (brachytherapy) for cancer that is confined to the prostate gland. The study will be the first multi-institutional evaluation of the treatment. To date, a number of single-institution studies have been conducted, showing the technique to be effective in controlling the disease.
Advertisement
PHILADELPHIA--The Radiation Therapy Oncology Group (RTOG) has just begun work on a potentially ground-breaking study of the use of radioactive seed implants (brachytherapy) for cancer that is confined to the prostate gland. The study will be the first multi-institutional evaluation of the treatment. To date, a number of single-institution studies have been conducted, showing the technique to be effective in controlling the disease.
The new RTOG investigation will look closely at the potential side effects of prostate brachytherapy as well as its effectiveness, said Colleen Lawton, MD, study chair. Dr. Lawton is a radiation oncologist at the Medical College of Wisconsin, Milwaukee.
Articles in this issue
almost 28 years ago
Vinorelbine/Cisplatin Improves Survival In Advanced NSCLCalmost 28 years ago
Centers Selected for STAR, Study of Tamoxifen and Raloxifenealmost 28 years ago
HDC/PBSC for Advanced Breast Cancer Debatedalmost 28 years ago
New Programs Aim to Improve Home Care Servicesalmost 28 years ago
Breast Cancer Patients Sought for Study of Premature Menopausealmost 28 years ago
Study Update Shows Improved Survival With Anastrozolealmost 28 years ago
New Colon Cancer Mouse Model First to Mimic Human Diseasealmost 28 years ago
Best Use of Breast Cancer Genetics Presents Clinical Challengealmost 28 years ago
Families Share Pleasure and Pain at The Marchalmost 28 years ago
Panel Lists 13 Areas for Emphasis in NCI Breast Cancer ResearchAdvertisement
Related to this article
In a phase 3 trial, the Breast Cancer Locator was noninferior to wire localization and lowered positive margin rates in nonpalpable breast cancer.
ASCENT-03 subgroup data show sacituzumab govitecan improved PFS vs chemotherapy across subgroups in untreated metastatic TNBC.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Bispecific antibodies targeting PD-L1 showed activity across first-, second-, and later-line advanced neuroendocrine carcinoma in 3 trials presented at ESMO 2026.
Petosemtamab plus pembrolizumab cut the risk of death by 50% vs pembrolizumab alone in first-line recurrent or metastatic PD-L1–positive head and neck cancer.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
The phase 3 IMpactMF study will be discontinued after an independent committee determined it was unlikely to meet its primary end point of overall survival.
Advertisement
Advertisement
Trending on CancerNetwork
1
New ASTRO Guideline Backs Hypofractionated Radiation in Prostate Cancer
2
Pembrolizumab Plus Chemo Improves PFS in PD-L1+ HR+/HER2– Breast Cancer
3
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
4
CEA-High Expression Shows Early Promise as a Biomarker for BG-C477 in NSCLC
5